This suggests that GABA analogs like gabapentin may not only inhibit BCAT1 directly but also potentially enhance the effects of TKIs, providing a promising therapeutic approach for targeting BCAT1 in cancer [50]. This evidence concerns the gene BCAT1 and cancer.